HOXB7 is an ER cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance

Why breast cancers become resistant to tamoxifen despite continued expression of the estrogen receptor alpha (ER) and what factors are responsible for high HER2 expression in these tumors remains an enigma. HOXB7 ChIP analysis followed by validation showed that HOXB7 physically interacts with ER, and that the HOXB7-ER complex enhances transcription of many ER target genes including HER2. Investigating strategies for controlling HOXB7, our studies revealed that MYC, stabilized via phosphorylation mediated by EGFR-HER2 signaling, inhibits transcription of miRNA-196a, a HOXB7 repressor. This leads to increased expression of HOXB7, ER-target genes and HER2. Repressing MYC using small molecule inhibitors reverses these events, and causes regression of breast cancer xenografts. The MYC-HOXB7-HER2 signaling pathway is eminently targetable in endocrine-resistant breast cancer.

4

Jin K, Park S, Teo WW, Korangath P, Cho SS, Yoshida T, Győrffy B, Goswami CP, Nakshatri H, Cruz LA, Zhou W, Ji H, Su Y, Ekram M, Wu Z, Zhu T, Polyak K, Sukumar S